Results 11 to 20 of about 34,432 (188)
Role of body mass index in outcomes of patients hospitalized with COVID‐19 illness
Obesity Science &Practice, Volume 8, Issue 6, Page 748-756, December 2022., 2022 Abstract Background Since the start of coronavirus disease 2019 (COVID‐19) pandemic, several studies have linked obesity with severity of illness as well as mortality in patients with COVID‐19. Outcomes of patients with overweight or obesity, who develop critical illness, have been studied extensively over the past decade where the studies have shown ...
Maleeha Zahid +8 more
wiley +1 more source
Using Twitter Data to Understand Public Perceptions of Approved versus Off-label Use for COVID-19-related Medications [PDF]
amiajnl-2022-012337.R1, 2022 Understanding public discourse on emergency use of unproven therapeutics is crucial for monitoring safe use and combating misinformation. We developed a natural language processing-based pipeline to comprehend public perceptions of and stances on coronavirus disease 2019 (COVID-19)-related drugs on Twitter over time.
arxiv +1 more source
Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions
Journal of Pharmacy & Pharmaceutical Sciences, 2021 Purpose: Remdesivir, a drug originally developed against Ebola virus, is currently recommended for patients hospitalized with coronavirus disease of 2019 (COVID-19).
Subrata Deb, Anthony Allen Reeves
doaj +1 more source
CPT: Pharmacometrics &Systems Pharmacology, Volume 12, Issue 1, Page 13-26, January 2023., 2023 Abstract The pharmacokinetics (PKs) and safety of medications in particular groups can be predicted using the physiologically‐based pharmacokinetic (PBPK) model. Using the PBPK model may enable safe pediatric clinical trials and speed up the process of new drug research and development, especially for children, a population in which it is relatively ...
Xu Zhou +5 more
wiley +1 more source
Acta Paediatrica, Volume 112, Issue 1, Page 19-33, January 2023., 2023 Abstract Aim Sweden initially chose a different disease prevention and control path during the pandemic than many other European countries. In June 2020, the Swedish Government established a National Commission to examine the management of COVID‐19 in Sweden. This paper summarises, and discusses, its findings.
Jonas F. Ludvigsson
wiley +1 more source
Remdesivir in treating hospitalized patients with COVID-19: A renewed review of clinical trials
Frontiers in Pharmacology, 2022 Since December 2019, COVID-19 has spread across the world almost through 2.5 years. As of 16 June 2022, the cumulative number of confirmed cases of COVID-19 worldwide has reached 542.62 million, and the death toll has risen to 6.33 million.
Zhenchao Wu +7 more
doaj +1 more source
The Clinical Respiratory Journal, Volume 17, Issue 1, Page 40-49, January 2023., 2023 When a disease or treatment is rapidly changing, traditional (static) predictive models may lose their accuracy. We show that in 7041 patients of whom 534 (7.6%) required invasive mechanical ventilation or died within 14 days that rolling logistic regression models improved both discrimination and the areas under the precision‐recall curves—all p < 0 ...
Milo Engoren +4 more
wiley +1 more source
Drug shortages: A systems view of the current state
Decision Sciences, Volume 53, Issue 6, Page 969-984, December 2022., 2022 ABSTRACT The objective of this thought leadership article is to create a systems view of drug shortages based on the perceptions of practitioners and policymakers. We develop a comprehensive framework describing what stakeholders are currently doing when faced with drug shortages and show the outcomes of their actions.
Kim E. van Oorschot +4 more
wiley +1 more source
European Journal of Clinical Investigation, Volume 53, Issue 1, January 2023., 2023 Graphical abstract MP3‐pulses‐COVID‐19 trial. Abstract Background The efficacy and safety of high versus medium doses of glucocorticoids for the treatment of patients with COVID‐19 has shown mixed outcomes in controlled trials and observational studies.
Luis Corral‐Gudino +21 more
wiley +1 more source
Acta Medica Iranica, 2022 Remdesivir, an antiviral medication, became an early promising therapeutic candidate for coronavirus disease 2019 (COVID-19) due to its ability to inhibit the virus in vitro. Current evidence about remdesivir treatment has been very controversial, so we
Azar Hadadi +12 more
doaj +1 more source